DANVILLE, Pa. – Geisinger, in partnership with AposHealth, today announced that a new non-invasive, drug-free treatment for patients suffering knee pain from osteoarthritis will be available to Geisinger Health Plan’s commercial members in Pennsylvania starting on April 1. AposHealth treatment is available exclusively at Geisinger in Central and Northeast Pennsylvania.
Developed by experts in orthopedics and sports medicine, the AposHealth device is approved by the U.S. Food and Drug Administration to help temporarily reduce knee pain and improve lower extremity function.
The AposHealth program is a year-long, at-home treatment that requires patients to wear a personalized device for approximately one hour a day during normal daily activities. Supported by more than 60 clinical studies, including recent research published in The Journal of the American Medical Association (JAMA), patients using the AposHealth system have experienced significant improvements in temporary pain relief, function and gait patterns.
“Providing personalized treatments for individual conditions is a tenet of Geisinger’s approach to musculoskeletal care,” said Michael Suk, MD, JD, Chief Physician Officer, System Services and Chair of the Musculoskeletal Institute at Geisinger. “AposHealth’s at-home treatment is perfectly aligned with our way of thinking of managing total health. Embracing new technologies and treatments allows us to reimagine the care pathway for knee osteoarthritis.”
“We are excited to be part of the innovative approach to treating knee pain taken by Geisinger, a Center of Excellence for Knee Replacements. This partnership brings a convenient, clinically proven knee osteoarthritis treatment option to patients and provides clinicians with an alternative non-invasive option,” added Cliff Bleustein, MD President and CEO of AposHealth®.
The AposHealthtreatment is currently available to Geisinger Health Plan’s commercial members in selected Geisinger locations in Danville, Wilkes-Barre and Scranton. Throughout 2021 Geisinger will be exploring opportunities to make this treatment available to more Geisinger patients across the it’s footprint in Central Pennsylvania. Please call 800-275-6401 to schedule an appointment.
AposHealth® is a global leader in the identification and treatment of gait-related conditions. The AposHealth®’s foot-worn “Apos3” device is FDA-cleared for treating knee osteoarthritis, to help temporarily reduce knee pain and improve lower extremity function during activities of daily living. It is also a non-FDA cleared wellness device which can help patients live well with other gait-related conditions such as chronic low back and hip pain. With a mission to advance global health through the power of movement, the AposIQ business unit combines innovative technology, data science and over a decade of experience in gait modification to determine the optimal way to adjust patients’ gaits over time.
Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes nine hospital campuses, a health plan with more than half a million members, two research centers and the Geisinger Commonwealth School of Medicine. With nearly 24,000 employees and more than 1,600 employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually. Learn more at www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.
This press release originally appeared here.